AstraZeneca licenses 3 programs under X-Chem collaboration
This article was originally published in Scrip
Executive Summary
AstraZeneca licensed three discovery programs for previously "undruggable" disease targets under a collaboration that takes advantage of X-Chem's library of small molecules and screening technology.